In particular, immune checkpoint blockades have been created employing antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1), and programmed cell death ligand-1 (PD-L1), and some of these compounds have been authorized for the treatment of hematological malignancies. Here, CD274 is linked to hematologic disorder.